Skip to content

Other geography segments

IL
$1.24M-5.1%

Similar metrics at other companies

Opko Health logo
OPKUS — PP&E (Net)
$20.28M-24.0%
Worthington Enterprises logo
WORUS — PP&E (Net)
$223.12M+7.4%
Orthofix Medical Inc. logo
OFIXUS — PP&E (Net)
$111.04M-4.6%
Advantage Solutions Inc. logo
ADVUS — PP&E (Net)
$114.8M+18.2%
Kodiak Sciences Inc logo
KODUS — PP&E (Net)
$32.1M-9.8%
EyePoint, Inc.
 logo
EYPTUS — PP&E (Net)
$9.02M+10.3%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s us — pp&e (net).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s US — PP&E (net)?
Rafael Holdings, Inc. (RFL) reported US — PP&E (net) of $359K in Q1 2026.
How has Rafael Holdings, Inc.'s US — PP&E (net) changed year-over-year?
Rafael Holdings, Inc.'s US — PP&E (net) decreased by 73.1% year-over-year, from $1.33M to $359K.
What does US — PP&E (net) mean?
Represents the net book value of tangible long-term assets located within the US segment, calculated as the original cost of property, plant, and equipment minus accumulated depreciation and impairment charges. This metric reflects the company's investment in physical infrastructure and operational capacity required to support its clinical research and pharmaceutical development activities in the region.